Single-agent Atezolizumab Improves Survival in PD-L1-High NSCLC

Atezolizumab monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment in patients with wild-type non –small cell lung cancer with PD-L1 expression ≥50%.

Source: CancerNetwork - November 11, 2019 Category: Cancer & Oncology Authors: Brittany Lovely Source Type: news